The Ministry of Health of the Republic of Uzbekistan The Pharmaceutical Industry Development Agency
Ру O`z Ўз En

Nobel Pharmsanoat Is Going to Launch Production of Kovipir, a Drug Based on Favipiravir Active Ingredient

Nobel Pharmsanoat Company, operating in Uzbekistan, has begun the process of state registration of Kovipir, a drug based on Favipiravir active ingredient.

Nobel Pharmsanoat is a company founded to a direct investment of Ulkar Holding - Nobel Ilac, one of the 100 most popular companies in Turkey, and has been operating in Uzbekistan since 2002. The enterprise is engaged in the production of 73 types, 150 forms of modern pharmaceutical products meeting international GMP standards. These products are supplied to the domestic market and exporting to foreign countries. The company employs 395 specialists.

According to Shamshod Sharipov, Quality Director, Nobel Pharmsanoat Company, the patent for the drug belongs to the Japanese Toyama Chemical Company. It has been proven that this drug, which has a wide spectrum of action against viruses RNA stores (influenza, rhinovirus, respiratory viruses, etc.), has a positive antiviral effect and has been used to treat patients with coronavirus in Japan since February 2020. Earlier this month, Zhejiang Hisun Pharmaceutical Co. Ltd. of China began production of this drug under the brand name Favilavir. In May, the ChemRar Company together with the Investment Fund of Russia launched the production of Avifavir in Russia.

Nobel Pharmsanoat Company will produce the antiviral Kovipir, primarily for the needs of Uzbekistan, and for exporting.

 

Click on the button below to listen to the text Powered by GSpeech